Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection

Clinical Microbiology and Infection

Volumn 21, Issue 2, 2015, Pages 197-203

  Song, L W ^a   Liu, P G ^b   Liu, C J ^c   Zhang, T Y ^a   Cheng, X D ^d   Wu, H L ^c   Yang, H C ^c   Hao, X K ^d   Yuan, Q ^a,b   Zhang, J ^a,b   Kao, J H ^c   Chen, D S ^c   Chen, P J ^c   Xia, N S ^a,b  

^a National Institute of Diagnostics and Vaccine Development in Infectious Diseases   (China)

^b XIAMEN UNIVERSITY   (China)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B (CHB); Hepatitis activity; Host immune status; Natural history of CHB; Quantitative anti HBc

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN;

ADULT; ARTICLE; BLOOD DONOR; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE STATUS; IMMUNOLOGICAL TOLERANCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIRUS LOAD; VIRUS REPLICATION; ADOLESCENT; AGED; BLOOD; CHILD; CHRONIC HEPATITIS B; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; IMMUNOLOGY; INFANT; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

HEPATITIS B VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INFANT; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84984580941     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.10.002     Document Type: Article

References (18)

1. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. JHepatol 2012, 57:167-185.
2. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49:S45-S55.
3. Rijckborst V., Hansen B.E., Cakaloglu Y., Ferenci P., Tabak F., Akdogan M., et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010, 52:454-461.
4. Moucari R., Mackiewicz V., Lada O., Ripault M.P., Castelnau C., Martinot-Peignoux M., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49:1151-1157.
5. Lee J.M., Ahn S.H., Kim H.S., Park H., Chang H.Y., Kim do Y., et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011, 53:1486-1493.
6. Tseng T.C., Liu C.J., Su T.H., Wang C.C., Chen C.L., Chen P.J., et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011, 141:517-525. e1-2.
7. Tseng T.C., Liu C.J., Yang H.C., Su T.H., Wang C.C., Chen C.L., et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2012, 55:68-76.
8. Hoofnagle J.H., Seeff L.B., Bales Z.B., Zimmerman H.J. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. NEngl J Med 1978, 298:1379-1383.
9. Li A., Yuan Q., Huang Z., Fan J., Guo R., Lou B., et al. Novel double-antigen sandwich immunoassay for human hepatitis B core antibody. Clin Vaccine Immunol 2010, 17:464-469.
10. Yuan Q., Song L.W., Liu C.J., Li Z., Liu P.G., Huang C.H., et al. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut 2013, 62:182-184.
11. Sun J., Yuan Q., Xie Q., Fan R., Tan D., Ning Q., et al. Baseline quantitative hepatitis B core antibody is the strongest predictor for 2-year HBeAg seroconversion in HBeAg positive CHB patients treated with telbivudine alone or combined with adefovir. In: American Association for the Study of Liver Diseases Abstracts; 2013. Hepatology 2013, 701A.
12. Huang C.H., Yuan Q., Chen P.J., Zhang Y.L., Chen C.R., Zheng Q.B., et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. JHepatol 2012, 57:720-729.
13. World Health Organization. WHO international standard: first international standard for anti-hepatitis B core antigen. Available from: [accessed 10.11.08]. http://www.nibsc.ac.uk/documents/ifu/95-522.pdf.
14. Yeh S.H., Tsai C.Y., Kao J.H., Liu C.J., Kuo T.J., Lin M.W., et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. JHepatol 2004, 41:659-666.
15. Marc G., Ghany T.J.L. Acute viral hepatitis. Atlas of gastroenterology 2009, 623-635. J. Wiley, New York, [Chapter 56]. T. Yamada (Ed.).
16. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005, 5:215-229.
17. Chien R.N., Liaw Y.F., Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999, 30:770-774.
18. Yuen M.F., Yuan H.J., Hui C.K., Wong D.K., Wong W.M., Chan A.O., et al. Alarge population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 2003, 52:416-419.